Cord Blood Transplantation Study (COBLT)

Note that you will be prompted to log in or register an account

Accession Number
HLB00590707a

Study Type
Epidemiology Study

Collection Type
Open BioLINCC Study See bottom of this webpage for request information

Study Period
March 1999 - December 2003

NHLBI Division
DBDR

Dataset(s) Last Updated
January 3, 2018

Related Studies
CBB

Consent

Commercial Use Data Restrictions No

Data Restrictions Based On Area Of Research No

Specific Consent Restrictions
None

Objectives

The transplant center protocol was a phase II multicenter trial to determine if banked unrelated donor umbilical cord blood could serve as an adequate hematopoietic stem cell source for adults and children with malignancies, immune deficiencies, inherited marrow failure, or inborn errors of metabolism. The largest strata studied pediatric patients with various leukemias. Each participating transplant center used the same patient selection criteria, preparative regimen for patients in the same class, initial graft-versus-host disease (GvHD) prophylaxis, indications for the use of cytokines, definitions for events and complications, and methods for evaluating immune reconstitution. The main study evaluated the impact of HLA 3/6 and 4/6 matching on outcome. The primary endpoint was 180-day disease free survival after UCBU transplantation. Secondary endpoints included engraftment, the frequency and severity of acute and chronic GvHD with stratification by degree of HLA match, overall survival, and immunologic reconstitution. Search activity was initiated in November 1998 and the first UCBU transplant was in March 1999. Enrollment in the COBLT transplant protocol ended December 31, 2003 with the accrual of 364 transplant recipients.

Background

Compared to other stem cell sources, cord blood is easier and safer to procure, has no donor attrition, a limitless supply, reduced viral transmission, less acute and chronic graft-versus-host-disease, is rich in hematopoietic progenitor cells, and immaturity of T-cell-mediated immunity. However, cord blood also has delayed neutrophil and platelet engraftment, a prolonged immune reconstitution, uncertain graft-versus-tumor activity, and cell doses from single cord blood units are a limiting factor for larger recipients.

Design

The Cord Blood Transplantation (COBLT) Study was comprised of three cord blood banks, seven core transplant centers and a data coordinating center. Funding was initiated in 1996 and the first two years of the project focused on the establishment of three cord blood banks and the development of validated Standard Operating Procedures for the recruitment of cord blood donors and collection, processing, testing and storage of umbilical cord blood units (UCBUs). The transplant protocol and Manual of Procedures for the clinical trial were also developed during this time by the original seven participating transplant centers. Additional centers were recruited to reach accrual goals and the transplant protocol was initiated at 26 participating institutions.

Additional Details

Subjects:

364 Subjects

Age:

Participants' age at transplant by stratum:

 

 STRATUM: Malignant disease, 5/6 or 6/6 HLA match, <=18 yearsSTRATUM: Malignant disease, 4/6 HLA match, <=18 yearsSTRATUM: Malignant disease, 3/6 HLA match, <=18 yearsSTRATUM: Severe aplastic anemia, Fanconi anemia and other marrow failure syndromesSTRATUM: Inborn errors of metabolism/storage diseases
N%N%N%N%N%
 11.3010.90..120.0011.43
Under 1 year22.60....120.001825.71
1 to 53646.752825.23..360.004462.86
6 to 102329.874338.74480.00..68.57
11 to 171519.483935.14120.00..11.43
18 to 54..........

 

 STRATUM: ImmunodeficienciesSTRATUM: Malignant disease alternative conditioning regimenSTRATUM: Adult patients, >18 yearsAll
N%N%N%N%
 ....411.7682.20
Under 1 year1250.00923.68..4211.54
1 to 51041.672360.53..14439.56
6 to 1028.3337.89..8122.25
11 to 17..37.89..5916.21
18 to 54....3088.24308.24
Sex:

Participants by stratum:

 

 STRATUM: Malignant disease, 5/6 or 6/6 HLA match, <=18 yearsSTRATUM: Malignant disease, 4/6 HLA match, <=18 yearsSTRATUM: Malignant disease, 3/6 HLA match, <=18 yearsSTRATUM: Severe aplastic anemia, Fanconi anemia and other marrow failure syndromesSTRATUM: Inborn errors of metabolism/storage diseases
N%N%N%N%N%
Male4051.957567.57240.00360.004564.29
Female3748.053632.43360.00240.002535.71

 

 STRATUM: ImmunodeficienciesSTRATUM: Malignant disease alternative conditioning regimenSTRATUM: Adult patients, >18 yearsAll
N%N%N%N%
Male1979.171642.111750.0021759.62
Female520.832257.891750.0014740.38

Donors by stratum:

 STRATUM: Malignant disease, 5/6 or 6/6 HLA match, <=18 yearsSTRATUM: Malignant disease, 4/6 HLA match, <=18 yearsSTRATUM: Malignant disease, 3/6 HLA match, <=18 yearsSTRATUM: Severe aplastic anemia, Fanconi anemia and other marrow failure syndromesSTRATUM: Inborn errors of metabolism/storage diseases
N%N%N%N%N%
 45.1921.80..120.0011.43
Male4153.256054.05240.00240.002941.43
Female3241.564944.14360.00240.004057.14
 STRATUM: ImmunodeficienciesSTRATUM: Malignant disease alternative conditioning regimenSTRATUM: Adult patients, >18 yearsAll
N%N%N%N%
 ..12.63411.76133.57
Male1041.672257.891647.0618250.00
Female1458.331539.471441.1816946.43

 

Race:

Participants by stratum:

 STRATUM: Malignant disease, 5/6 or 6/6 HLA match, <=18 yearsSTRATUM: Malignant disease, 4/6 HLA match, <=18 yearsSTRATUM: Malignant disease, 3/6 HLA match, <=18 yearsSTRATUM: Severe aplastic anemia, Fanconi anemia and other marrow failure syndromesSTRATUM: Inborn errors of metabolism/storage diseases
N%N%N%N%N%
 11.3010.90..120.0011.43
Black22.602320.72..120.0068.57
Other911.691311.71120.00..1622.86
White6584.427466.67480.00360.004767.14

 

 STRATUM: ImmunodeficienciesSTRATUM: Malignant disease alternative conditioning regimenSTRATUM: Adult patients, >18 yearsAll
N%N%N%N%
 14.17..38.8282.20
Black520.83821.0538.824813.19
Other14.17..38.824311.81
White1770.833078.952573.5326572.80


Donors by stratum:

 STRATUM: Malignant disease, 5/6 or 6/6 HLA match, <=18 yearsSTRATUM: Malignant disease, 4/6 HLA match, <=18 yearsSTRATUM: Malignant disease, 3/6 HLA match, <=18 yearsSTRATUM: Severe aplastic anemia, Fanconi anemia and other marrow failure syndromesSTRATUM: Inborn errors of metabolism/storage diseases
N%N%N%N%N%
 911.6976.31..120.0011.43
Black22.602018.02..240.0045.71
Other56.4965.41240.00..45.71
White6179.227870.27360.00240.006187.14

 

 STRATUM: ImmunodeficienciesSTRATUM: Malignant disease alternative conditioning regimenSTRATUM: Adult patients, >18 yearsAll
N%N%N%N%
 416.6725.26720.59318.52
Black416.6725.26..349.34
Other14.17..25.88205.49
White1562.503489.472573.5327976.65


 

Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.

Resources Available

Study Datasets Only

Study Documents

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.